Ceftriaxone and Tarceva drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ceftriaxone (ceftriaxone sodium) and Tarceva (erlotinib hydrochloride). Common drug interactions include cough among females and death among males.

The phase IV clinical study analyzes what interactions people have when they take Ceftriaxone and Tarceva. It is created by eHealthMe based on reports of 12 people who take the same drugs from the FDA, and is updated regularly.

What is Ceftriaxone?

Ceftriaxone has active ingredients of ceftriaxone sodium. It is often used in typhoid fever. eHealthMe is studying from 40,991 Ceftriaxone users. Check the latest studies of Ceftriaxone.

What is Tarceva?

Tarceva has active ingredients of erlotinib hydrochloride. It is often used in lung cancer. eHealthMe is studying from 31,036 Tarceva users. Check the latest studies of Tarceva.



On Jul, 09, 2026

12 people who take Ceftriaxone and Tarceva together, and have interactions are studied.

Ceftriaxone and Tarceva drug interactions.

What are the common drug interactions of Ceftriaxone and Tarceva, by gender? *:

female:

  1. Cough
  2. Disease progression
  3. Gastrointestinal infection (infection of stomach and intestine)
  4. Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
  5. Hypovolaemia (a decreased volume of circulating blood in the body)
  6. Large intestine perforation (hole in large intestine)
  7. Lung disorder (lung disease)
  8. Mental status changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation)
  9. Nausea (feeling of having an urge to vomit)
  10. Peritonitis (inflammation of the peritoneum, the thin tissue that lines the inner wall of the abdomen and covers most of the abdominal organs)

male:

  1. Death
  2. Acne (skin problems that cause pimples)
  3. Dry skin
  4. Dyspnoea (difficult or laboured respiration)
  5. Gamma-glutamyltransferase increased
  6. Rash pruritic (redness with itching)
  7. Ill-defined disorder
  8. Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
  9. Rash
  10. Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)

What are the common drug interactions of Ceftriaxone and Tarceva, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Cough
  2. Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)

50-59:

  1. Disease progression
  2. Dyspnoea (difficult or laboured respiration)

60+:

  1. Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
  2. Rash
  3. Hypovolaemia (a decreased volume of circulating blood in the body)
  4. Large intestine perforation (hole in large intestine)
  5. Lung disorder (lung disease)
  6. Mental status changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation)
  7. Nausea (feeling of having an urge to vomit)
  8. Peritonitis (inflammation of the peritoneum, the thin tissue that lines the inner wall of the abdomen and covers most of the abdominal organs)
  9. Pruritus (severe itching of the skin)
  10. Purulence (containing pus)

What are the existing conditions these people have? *

  1. Lung Neoplasm Malignant (cancer tumour of lung): 4 people, 33.33%
  2. Skin Candida (fungal infection of skin): 3 people, 25.00%
  3. Pneumonia Bacterial (pneumonia associated with bacterial infection): 3 people, 25.00%
  4. Lung Adenocarcinoma (a form of non-small cell lung cancer): 3 people, 25.00%
  5. Enterocolitis (inflammation of the digestive tract, involving enteritis of the small intestine and colitis of the colon): 3 people, 25.00%
  6. Enlarged Prostate: 3 people, 25.00%
  7. Lung Cancer - Non-Small Cell (lung cancer): 2 people, 16.67%
  8. Pancreatic Carcinoma (pancreatic cancer): 1 person, 8.33%
  9. Mesothelioma (rare type of cancer that occurs in the thin layer of cells lining the body's internal organs, known as the mesothelium): 1 person, 8.33%
  10. Hypercoagulation (increased tendency for clotting of the blood): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Ceftriaxone and Tarceva?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Ceftriaxone and Tarceva:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Ceftriaxone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Tarceva:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ceftriaxone and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Tarceva and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on ceftriaxone sodium and erlotinib hydrochloride (the active ingredients of Ceftriaxone and Tarceva, respectively), and Ceftriaxone and Tarceva (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: